p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

Di Leo, A ; Tanner, M ; Desmedt, C ; Paesmans, M ; Cardoso, F ; Durbecq, V ; Chan, S ; Perren, T ; Aapro, M ; Sotiriou, C ; Piccart, MJ ; Larsimont, D ; Isola, J

Annals of oncology, 2007-06, Vol.18 (6), p.997-1003 [Periódico revisado por pares]

Oxford: Oxford University Press

Texto completo disponível